Compare Procter & Gamble Health with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs NOVARTIS - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH NOVARTIS PROCTER & GAMBLE HEALTH/
NOVARTIS
 
P/E (TTM) x 55.4 512.7 10.8% View Chart
P/BV x 5.0 29.7 16.9% View Chart
Dividend Yield % 9.5 1.5 615.1%  

Financials

 PROCTER & GAMBLE HEALTH   NOVARTIS
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
NOVARTIS
Mar-18
PROCTER & GAMBLE HEALTH/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs3,549758 468.2%   
Low Rs1,301579 224.7%   
Sales per share (Unadj.) Rs511.4228.4 223.9%  
Earnings per share (Unadj.) Rs61.331.7 193.1%  
Cash flow per share (Unadj.) Rs74.032.8 225.9%  
Dividends per share (Unadj.) Rs440.0010.00 4,400.0%  
Dividend yield (eoy) %18.11.5 1,212.9%  
Book value per share (Unadj.) Rs927.8297.1 312.2%  
Shares outstanding (eoy) m16.6024.69 67.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.9 162.0%   
Avg P/E ratio x39.621.1 187.9%  
P/CF ratio (eoy) x32.820.4 160.6%  
Price / Book Value ratio x2.62.2 116.2%  
Dividend payout %717.931.5 2,278.5%   
Avg Mkt Cap Rs m40,25716,505 243.9%   
No. of employees `0001.10.7 169.8%   
Total wages/salary Rs m1,3131,445 90.8%   
Avg. sales/employee Rs Th7,486.78,441.3 88.7%   
Avg. wages/employee Rs Th1,157.62,163.6 53.5%   
Avg. net profit/employee Rs Th897.21,173.1 76.5%   
INCOME DATA
Net Sales Rs m8,4905,639 150.6%  
Other income Rs m2441,718 14.2%   
Total revenues Rs m8,7347,357 118.7%   
Gross profit Rs m1,482-63 -2,370.6%  
Depreciation Rs m21125 834.8%   
Interest Rs m055 0.0%   
Profit before tax Rs m1,5141,575 96.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m563792 71.1%   
Profit after tax Rs m1,017784 129.8%  
Gross profit margin %17.5-1.1 -1,574.5%  
Effective tax rate %37.150.3 73.9%   
Net profit margin %12.013.9 86.2%  
BALANCE SHEET DATA
Current assets Rs m15,3439,522 161.1%   
Current liabilities Rs m1,9603,296 59.5%   
Net working cap to sales %157.6110.4 142.8%  
Current ratio x7.82.9 271.0%  
Inventory Days Days4937 133.1%  
Debtors Days Days2828 100.1%  
Net fixed assets Rs m1,20946 2,628.9%   
Share capital Rs m166123 134.5%   
"Free" reserves Rs m15,2357,213 211.2%   
Net worth Rs m15,4017,336 209.9%   
Long term debt Rs m00-   
Total assets Rs m17,59511,105 158.4%  
Interest coverage xNM29.5-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 95.0%   
Return on assets %5.87.6 76.5%  
Return on equity %6.610.7 61.8%  
Return on capital %10.322.2 46.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63661 2,700.2%   
Fx outflow Rs m4,3683,630 120.3%   
Net fx Rs m-2,732-3,570 76.5%   
CASH FLOW
From Operations Rs m-1,3041,610 -81.0%  
From Investments Rs m12,697687 1,848.2%  
From Financial Activity Rs m-301-2,677 11.2%  
Net Cashflow Rs m11,093-380 -2,922.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 75.0 69.1%  
Indian inst/Mut Fund % 18.2 2.0 910.0%  
FIIs % 1.0 1.6 62.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 21.5 135.3%  
Shareholders   28,591 41,647 68.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Sep 20, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS